- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02460211
Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D (ASSESS-D)
1 aprile 2021 aggiornato da: Intermountain Health Care, Inc.
Each patient who is admitted for preoperative preparation for elective open heart surgery at Intermountain Medical Center will be invited to participate in this study.
After a written informed consent is obtained, patients meeting inclusion/exclusion criteria will be randomized 1:1 to the treatment arm or placebo/control arm.
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on the mornings of post-op days 1 and 2. Blood will be obtained at the following time periods: 1) At baseline pre-procedure 12 to 18 hours before planned surgery; 2) Post-operative day 1, 12 to 24 hours after surgery; 3) 48 hours after surgery; 4) 72 hours after surgery; 5) At discharge (estimated to be between 5-8 days after surgery); and 6) At the 6-month follow-up visit (post-surgery).
Plasma levels of 25(OH) vitamin D will be measured on each sample.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Each patient who is admitted for preoperative preparation for elective open heart surgery at Intermountain Medical Center will be invited to participate in this study.
The patient's history and medical records will be reviewed and data gathered will be used to evaluate the patient's relationship to inclusion and exclusion criteria.
After a written informed consent is obtained, subjects will be randomized 1:1 to the treatment arm or placebo/control arm.
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on the mornings of post-op days 1 and 2. Approximately 15-20 ml (about one tablespoon) of blood will be obtained at the following time periods (+/- 4 hours): 1) At baseline pre-procedure 12 to 18 hours before planned surgery; 2) Post-operative day 1, 12 to 24 hours after surgery; 3) 48 hours after surgery; 4) 72 hours after surgery; 5) At discharge (estimated to be between 5-8 days after surgery); and 6) At the 6-month follow-up visit (post-surgery).
Each blood sample will be transported to The Center for Molecular and Genetic Research at LDS Hospital Cardiovascular Genetics Laboratory for preparation and storage.
Plasma levels of 25(OH) vitamin D will be measured on each sample.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
150
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Utah
-
Murray, Utah, Stati Uniti, 84143
- Intermountain Heart Institute
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Male or female >= 18 years of age
- Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures
- Subject is scheduled for elective open heart surgery at Intermountain Medical Center
- Subject is relatively stable as assessed by the Principal Investigator
Exclusion Criteria:
- Inability or refusal of the patient and/or the patient's legally acceptable representative to provide written informed consent for any reason.
- History of previous vitamin D supplementation > 1,000 units of vitamin D3 per day within the past three months.
- Evidence of hypercalcemia on screening labs (> 10.5 milligrams per deciliter of blood).
- Any scheduled cardiac surgical procedure that does not require open thoracotomy (the reason for this exclusion is that the study design requires that the patients will undergo a significantly stressful procedure, which can be generally guaranteed if the patient undergoes open thoracotomy).
- Known allergic reaction or other intolerance to oral vitamin D3.
- Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Principal Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.
- Subject participation in previous investigational interventional studies within 30 days of the current study.
- Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Treatment
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
|
Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
|
|
Comparatore placebo: Placebo/Control Arm
Those randomized to the control arm will receive three oral placebo doses.
|
Those randomized to the control arm will receive three placebo doses.
The first dose will be given the evening before surgery.
The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Changes in 25(OH) vitamin D levels (ng/ml) between baseline (pre-surgery) and 72 hours post-surgery.
Lasso di tempo: 72 hours
|
72 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Comparison of 25(OH) vitamin D levels (ng/ml) between baseline and other time points.
Lasso di tempo: 12-24 hrs, 48 hrs, discharge (approximately 5-8 days post-surgery), 6 months
|
Subjects will be re-assessed on post-operative day 1 (12-24 hours after surgery), then at 48 and 72 hours post-surgery, at discharge (approximately 5-8 days post-surgery), and at a 6 month post-surgery follow-up visit.
|
12-24 hrs, 48 hrs, discharge (approximately 5-8 days post-surgery), 6 months
|
|
Percent differences in adverse clinical outcomes between the vitamin D3 supplementation treatment and placebo arms.
Lasso di tempo: 6 months
|
Clinical outcomes that will be monitored include: death, myocardial infarction, stroke, repeat coronary revascularization or hospitalization for heart failure, worsening of renal function, hospitalization for pneumonia or other acute systemic infection or any other serious adverse clinical event.
|
6 months
|
|
Time to adverse clinical events stratified by vitamin D3 supplementation and placebo arms.
Lasso di tempo: 6 months
|
Clinical outcomes that will be monitored include: death, myocardial infarction, stroke, repeat coronary revascularization or hospitalization for heart failure, worsening of renal function, hospitalization for pneumonia or other acute systemic infection or any other serious adverse clinical event.
|
6 months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Joseph B Muhlestein, MD, Intermountain Health Care, Inc.
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 luglio 2015
Completamento primario (Effettivo)
1 ottobre 2018
Completamento dello studio (Effettivo)
1 ottobre 2020
Date di iscrizione allo studio
Primo inviato
8 aprile 2015
Primo inviato che soddisfa i criteri di controllo qualità
29 maggio 2015
Primo Inserito (Stima)
2 giugno 2015
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
5 aprile 2021
Ultimo aggiornamento inviato che soddisfa i criteri QC
1 aprile 2021
Ultimo verificato
1 aprile 2021
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 1040458
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Vitamin D3
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkCompletatoEmicrania secondo i criteri della International Headache Society (IHS) (ICHD-II)Danimarca
-
Alcon ResearchCompletato
-
Boston Children's HospitalCompletato
-
Tata Memorial CentreReclutamento
-
Riphah International UniversityReclutamentoVerruca plantare | Verruca | Verruca comune | Mano di verruche | Verruca piatta | Verruca virale | Verruche comuni (Verruca Vulgaris) | Verruche del piedePakistan
-
Cairo UniversityNon ancora reclutamentoTrattamento delle verruche plantari
-
University of California, San FranciscoCompletato
-
The Affiliated Hospital of Qingdao UniversityNon ancora reclutamentoEmicolectomia destra | Carcinoma colorettale (CRC)Cina
-
Cedars-Sinai Medical CenterTerminatoCarenza di vitamina D | Morbo di CrohnStati Uniti